SFTSV GN Specific Neutra™ Antibody Products

Are you struggling with low antibody efficacy, inconsistent neutralization data, or delayed SFTSV research progress? Creative Biolabs' SFTSV GN-specific Neutra™ antibody products leverage advanced single-B cell screening and structural epitope mapping to deliver high-affinity antibodies that reliably neutralize SFTSV, accelerating therapeutic development and diagnostic innovation.

Introduction to SFTSV GN

Severe fever with thrombocytopenia syndrome virus Gn glycoprotein (SFTSV GN) is a pivotal surface antigen driving viral entry and pathogenesis. As a critical component of the viral envelope, GN interacts with host receptors to mediate cellular adhesion and membrane fusion. Its structural and functional conservation across phleboviruses makes it a prime target for therapeutic intervention and vaccine design.

• Basic Information

SFTSV GN is a class II viral fusion protein encoded by the M segment of the tripartite SFTSV RNA genome. Expressed as a precursor polypeptide, it undergoes post-translational cleavage to form mature GN and GC heterodimers. GN dominates the virion surface, directly engaging host cell receptors like non-muscle myosin heavy chain IIA (NMHC-IIA). Its antigenic stability and high immunogenicity correlate with survival rates in SFTS patients, where GN-specific neutralizing antibodies are pivotal for viral clearance and clinical recovery.

Fig.1 SFTSV replication cycle and pharmacological intervention targets.¹

• Structural Insights

The GN ectodomain comprises three β-sheet-rich domains (DI-DIII) arranged in a spike-like trimer. Cryo-EM studies reveal that neutralizing antibodies primarily target conformational epitopes on DI and DII, which are critical for receptor binding and immune evasion. Such structural precision enables the design of antibodies that resist viral escape mutants.

Fig.2 Genomic structure of SFTSV.¹

• Signaling Pathways

SFTSV GN-mediated entry activates pro-inflammatory pathways (e.g., NF-κB and MAPK) and suppresses interferon responses, exacerbating thrombocytopenia and tissue damage. GN-specific antibodies counteract these effects by neutralizing extracellular virions, reducing viral load, and mitigating cytokine storms—key mechanisms for preventing multi-organ failure.

• Disease Implications

SFTSV infection causes severe fever, thrombocytopenia, and hemorrhagic complications, with mortality rates up to 30%. The absence of GN-specific IgG in patient sera correlates with uncontrolled viremia and fatal outcomes, underscoring the therapeutic necessity of neutralizing antibodies.

Applications of SFTSV GN Neutralizing Antibodies

• Therapeutic Development

Monoclonal antibodies demonstrate prophylactic and therapeutic efficacy in vivo. Early administration (within 24 hours post-infection) reduces viral titers by 2–3 logs, restores platelet counts, and prevents endothelial damage in lung, liver, and kidney tissues. Their cross-reactivity with emerging phleboviruses offers broad-spectrum potential.

• Diagnostic Assays

High-affinity GN antibodies enable rapid SFTSV detection in serum via lateral flow assays, with 99% specificity. Quantitative ELISAs using these antibodies track neutralizing titers in vaccinated individuals, supporting vaccine efficacy studies and serosurveillance in endemic regions.

• Vaccine Design

GN-specific antibodies guide epitope-focused vaccine development. Trimeric GN subunits, modeled using antibody-defined epitopes, induce neutralizing antibodies in preclinical trials. DNA vaccines encoding GN elicit robust IgG responses in murine models, validating its role as a protective antigen.

Our Anti-SFTSV GN Antibody Products

Anti-SFTSV GN antibody includes monoclonal and single-domain antibodies (nanobodies) engineered for high neutralization potency. For example: 1) Cross-neutralizes SFTSV, Heartland virus, and Guertu virus by targeting a conserved DI epitope, achieving >90% viral inhibition in murine models; 2) A camelid nanobody fused with human Fc, showing sub-µg/mL IC₅₀ values and rapid viral clearance in humanized mice. 3) Binds novel DI epitopes to sterically hinder receptor interaction, validated via cryo-EM and live-virus neutralization assays.

Creative Biolabs offers SFTSV GN-specific Neutra™ antibody products combining cutting-edge epitope mapping, cross-reactive neutralization, and scalable manufacturing to empower your antiviral programs.

Contact our team today to explore custom solutions for your SFTSV research or therapeutic development.

REFERENCE

1. Dang, Huimin, et al. "Recent Advances in Therapeutics for Severe Fever with Thrombocytopenia Syndrome Virus." Viruses 17.9 (2025): 1174. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/v17091174